ALX Oncology’s (ALXO) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of ALX Oncology (NASDAQ:ALXO) in a report released on Friday,Benzinga reports. They currently have a $5.00 price objective on the stock.

ALXO has been the subject of a number of other reports. Jefferies Financial Group raised ALX Oncology from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $2.00 to $3.00 in a research note on Thursday. Piper Sandler lifted their target price on ALX Oncology from $8.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday. UBS Group reduced their target price on ALX Oncology from $4.00 to $2.20 and set a “buy” rating on the stock in a report on Monday, January 27th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a report on Friday, January 24th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $4.14.

ALX Oncology Stock Down 19.1 %

Shares of ALX Oncology stock opened at $1.06 on Friday. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. ALX Oncology has a 12 month low of $0.95 and a 12 month high of $17.83. The business has a fifty day simple moving average of $1.39 and a 200 day simple moving average of $1.62. The stock has a market cap of $55.91 million, a PE ratio of -0.36 and a beta of 1.01.

Institutional Trading of ALX Oncology

A number of institutional investors have recently modified their holdings of ALXO. Almitas Capital LLC bought a new stake in shares of ALX Oncology in the fourth quarter valued at about $2,042,000. Bank of America Corp DE lifted its holdings in shares of ALX Oncology by 492.9% in the fourth quarter. Bank of America Corp DE now owns 1,035,326 shares of the company’s stock valued at $1,729,000 after purchasing an additional 860,703 shares in the last quarter. Bank of Montreal Can bought a new stake in shares of ALX Oncology in the fourth quarter valued at about $1,380,000. Two Sigma Advisers LP lifted its holdings in shares of ALX Oncology by 64.6% in the fourth quarter. Two Sigma Advisers LP now owns 823,900 shares of the company’s stock valued at $1,376,000 after purchasing an additional 323,400 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of ALX Oncology in the third quarter valued at about $578,000. 97.97% of the stock is currently owned by institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.